American Type Culture Collection (ATCC) Logo American Type Culture Collection (ATCC) Logo Cart 0
  • Careers
  • Support

Pancreatic Cancer Organoid Panel, CDKN2A

ACP-1001

This patient-derived cancer panel contains three different vials of organoids. It can be used to model cyclin-dependent kinase inhibitor 2A (CDKN2A)-driven tumor biology and heterogeneity, enabling more predictive evaluation of biomarkers and emerging targeted or combination therapies. See the characteristics tab of this page for more information.  

This panel is offered at a built in 20% savings compared to purchasing the included organoid models individually.

In addition, eligible nonprofit organizations will receive up to an additional 45% off, making this panel a great option for research groups committed to advancing pancreatic cancer discovery and therapeutic development.

Product type
Organoid
Components

HCM-BROD-0015-C25, ATCC PDM-110

HCM-CSHL-0090-C25, ATCC PDM-37

HCM-CSHL-0088-C25, ATCC PDM-35

Applications
3D cell culture
Product format
Frozen
Storage conditions
Vapor phase of liquid nitrogen
Buy Now
Price: $9,070.00 ea
Discounts may be available for our fellow nonprofit organizations. Login to see your price.

Generally ships within 1-3 business days

Documentation

ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

Detailed product information

General

Specific applications

These pancreatic organoids retain native tumor morphology and cellular heterogeneity, enabling researchers to investigate pancreatic cancer biology and therapeutic vulnerabilities with greater clinical relevance. Key applications of this organoid panel include, but are not limited to:

  • Drug Screening & Sensitivity Testing
  • Mechanistic Studies of Pancreatic Cancer Progression
  • Biomarker Discovery & Validation
  • Comparative Studies Across Pancreatic Cancer Subtype
  • Preclinical Modeling for Novel Therapeutics
Additional information on these patient derived organoids, as well as all available patient derived models available through ATCC, can be found in the HCMI NCI searchable catalogue:

https://hcmi-searchable-catalog.nci.nih.gov/

Characteristics

Comments

Human-relevant patient-derived pancreatic cancer organoids present an opportunity to evaluate Cyclin‑dependent kinase inhibitor 2A (CDKN2A), which is a tumor suppressor gene frequently inactivated by somatic mutations across many cancers, including melanoma, gastrointestinal, and pancreatic malignancies, and germline mutations in CDKN2A confer inherited cancer risk. Despite its high prevalence, there are currently no approved therapies that directly target CDKN2A mutations. Adoptive cell therapy, particularly T‑cell receptor (TCR)–engineered T cell approaches, offers a promising strategy by targeting CDKN2A‑derived neoantigens presented by common HLA alleles—neoantigens absent from healthy cells—enabling selective tumor targeting. Both autologous and off‑the‑shelf allogeneic TCR‑engineered T cell therapies, alone or in combination with other immunotherapies, have the potential to provide broadly applicable, mutation‑specific treatments for patients with CDKN2A‑mutant cancers.

A panel of 3 pancreatic cancer organoids with varying degrees of genetic complexity. They have genomic mutation of Cyclin‑dependent kinase inhibitor 2A (CDKN2A).

Corresponding clinical data and genomic information can be accessed through the Human Cancer Models Initiative (HCMI) searchable catalog via the links below:

https://ocg.cancer.gov/programs/hcmi/resources

https://portal.gdc.cancer.gov/

Information associated with the individual pancreatic cancer organoids within the panel can be accessed via the links below:

https://hcmi-searchable-catalog.nci.nih.gov/model/HCM-BROD-0015-C25

https://hcmi-searchable-catalog.nci.nih.gov/model/HCM-CSHL-0090-C25

https://hcmi-searchable-catalog.nci.nih.gov/model/HCM-CSHL-0088-C25

Handling information

Handling procedure

Handling information including subculturing, cryopreservation, and associated media and reagents information can be found under the individual product pages for the organoids included in this panel: Linked below:

HCM-BROD-0015-C25, ATCC PDM-110

HCM-CSHL-0090-C25, ATCC PDM-37

HCM-CSHL-0088-C25, ATCC PDM-35

History

Special collection
Human Cancer Models Initiative (HCMI)

Legal disclaimers

Intended use
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
Warranty

The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid.  Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.

Disclaimers

This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.

Permits & Restrictions

Material Transfer Agreement Addendum for HUB/Organoid Products

A signed Material Transfer Agreement Addendum for HUB/Organoid Products is required to order this item. No further signed Addendum is required if it was previously submitted and processed in connection with a prior order. We cannot ship this item unless the signed Addendum is in place. To submit the signed Addendum, email it to [email protected] with a reference to both your account and sales order numbers. Once received, your Addendum will be reviewed, and this item will be released for shipment if all other requirements are met. If you need assistance with your order, please contact our Customer Care team or your applicable distributor.
MORE INFORMATION ABOUT PERMITS AND RESTRICTIONS

Frequently Asked Questions

References

For product-related inquiries and issues, contact Product Experience:

Message Us

Hours of Operation

Monday - Friday
9:00am - 5:00pm
US Eastern Time